Oncology Drug Advisory Committee
From Wikipedia, the free encyclopedia
The Oncology Drugs Advisory Committee (ODAC) receives requests for technical and clinical evaluation of new drugs by the US FDA. The committee, consisting of members from academic and clinical oncology biostatistics, the general public, and the pharmaceutical industry, makes non-binding recommendations to both the CDER and CBER divisions of the FDA about the advisability of approving new medications to treat cancer.
ODAC meetings are held regularly; the next meeting is scheduled for June 1, 2007.[1]
The current roster of ODAC members is publicly available. [2]
